WallStreetZenWallStreetZen

NASDAQ: GRCE
Grace Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for GRCE

Based on 1 analyst offering 12 month price targets for Grace Therapeutics Inc

Min Forecast
$12.00+328.57%
Avg Forecast
$12.00+328.57%
Max Forecast
$12.00+328.57%

Should I buy or sell GRCE stock?

Based on 1 analyst offering ratings for Grace Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GRCE stock forecasts and price targets.

GRCE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-18

1 of 1

Forecast return on equity

Is GRCE forecast to generate an efficient return?

Company
5.06%
Industry
118.54%
Market
79.49%
GRCE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GRCE forecast to generate an efficient return on assets?

Company
4.31%
Industry
38.01%
GRCE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GRCE earnings per share forecast

What is GRCE's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.85
Avg 2 year Forecast
-$0.57
Avg 3 year Forecast
$0.26

GRCE revenue forecast

What is GRCE's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$11.9M
Avg 2 year Forecast
$64.4M
Avg 3 year Forecast
$114.6M

GRCE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GRCE$2.80$12.00+328.57%Buy
SRZN$8.69$38.50+343.09%Strong Buy
CALC$2.06$14.50+603.88%Strong Buy
PYPD$2.72$11.00+304.41%Buy
INKT$6.92$19.50+181.75%Buy
View Top Biotech Stocks

Grace Therapeutics Stock Forecast FAQ

Is Grace Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GRCE) stock is to Buy GRCE stock.

Out of 1 analyst, 0 (0%) are recommending GRCE as a Strong Buy, 1 (100%) are recommending GRCE as a Buy, 0 (0%) are recommending GRCE as a Hold, 0 (0%) are recommending GRCE as a Sell, and 0 (0%) are recommending GRCE as a Strong Sell.

If you're new to stock investing, here's how to buy Grace Therapeutics stock.

What is GRCE's earnings growth forecast for 2026-2028?

(NASDAQ: GRCE) Grace Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Grace Therapeutics's earnings in 2025 is -$13,370,000.On average, 3 Wall Street analysts forecast GRCE's earnings for 2026 to be -$8,652,343, with the lowest GRCE earnings forecast at -$11,153,847, and the highest GRCE earnings forecast at -$6,388,112. On average, 2 Wall Street analysts forecast GRCE's earnings for 2027 to be -$5,729,021, with the lowest GRCE earnings forecast at -$6,996,504, and the highest GRCE earnings forecast at -$4,461,539.

In 2028, GRCE is forecast to generate $2,636,364 in earnings, with the lowest earnings forecast at $2,636,364 and the highest earnings forecast at $2,636,364.

What is GRCE's revenue growth forecast for 2027-2029?

(NASDAQ: GRCE) Grace Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.66%.

Grace Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast GRCE's revenue for 2027 to be $120,968,542, with the lowest GRCE revenue forecast at $13,790,211, and the highest GRCE revenue forecast at $228,146,873. On average, 1 Wall Street analysts forecast GRCE's revenue for 2028 to be $652,702,853, with the lowest GRCE revenue forecast at $652,702,853, and the highest GRCE revenue forecast at $652,702,853.

In 2029, GRCE is forecast to generate $1,162,028,071 in revenue, with the lowest revenue forecast at $1,162,028,071 and the highest revenue forecast at $1,162,028,071.

What is GRCE's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: GRCE) forecast ROA is 4.31%, which is lower than the forecast US Biotechnology industry average of 38.01%.

What is GRCE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GRCE price target, the average GRCE price target is $12.00, with the highest GRCE stock price forecast at $12.00 and the lowest GRCE stock price forecast at $12.00.

The Wall Street analyst predicted that Grace Therapeutics's share price could reach $12.00 by Feb 18, 2026. The average Grace Therapeutics stock price prediction forecasts a potential upside of 328.57% from the current GRCE share price of $2.80.

What is GRCE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: GRCE) Grace Therapeutics's current Earnings Per Share (EPS) is -$1.16. On average, analysts forecast that GRCE's EPS will be -$0.85 for 2026, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$0.63. On average, analysts forecast that GRCE's EPS will be -$0.57 for 2027, with the lowest EPS forecast at -$0.69, and the highest EPS forecast at -$0.44. In 2028, GRCE's EPS is forecast to hit $0.26 (min: $0.26, max: $0.26).

What is GRCE's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: GRCE) forecast ROE is 5.06%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.